Earnings Releases·Nov 5, 2026, 6:04 AM ET

BeOne Medicines — Third Quarter 2026 Earnings Summary

Q3 2026 total global revenue rose 34% YoY to $1.9 billion, while GAAP diluted EPS surged 201% to $3.28 and non-GAAP diluted EPS increased 73% to $4.59, driven by strong BRUKINSA sales ($1.4B) and improved gross margins (88% GAAP, 90% adjusted).
The company raised full-year 2026 guidance for total revenue to $6.9–$7.0 billion, GAAP operating income to $1.2–$1.3 billion, and non-GAAP operating income to $1.9–$2.0 billion, citing continued rapid global growth.
Strategic pipeline advancements include FDA Priority Review for BRUKINSA's MANGROVE filing, new regulatory approvals for TEVIMBRA in Japan and for a HER2+ GEA regimen, and a new collaboration with Revolution Medicines for RAS inhibitors in Asian markets.
Balance sheet strength remains robust with $5.87 billion in cash and equivalents as of September 30, 2026, and free cash flow increased 34% YoY to $474 million.